Should we repeat a dose-escalation trial for stage III NSCLC in the era of modern radiotherapy techniques and dose constraints?  

Would you consider a 2x2 design incorporating immunotherapy?



Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Yale School of Medicine
Great points made here. NRG LU008 is a recently ac...
Radiation Oncologist at Fort Bend Medical and Diagnostic Center
I wonder how insurance will bill for SBRT and chem...
Radiation Oncologist at Baylor Scott & White Health
I have personally done this with 5 patients over t...
Sign in or Register to read more